TIDE Genetics Launches a New Platform for Gene Editing Analysis
For over a decade, TIDE has been the go-to tool for quick, accessible gene editing analyses. But as gene editing advances and moves toward the clinic, a standalone tool is no longer enough.
TIDE Genetics has launched a new website that simplifies the experience of analyzing on-target gene editing, including CRISPR/Cas9.
TIDE has been an integral part of gene-editing analysis since its launch in 2014, but it has always been a standalone tool—powerful yet lacking the support and community that today's researchers and clinical teams need.
A new TIDE must serve more than just dedicated academic users. We needed to expand beyond the tool to make the experience more user-friendly. That's why the website now fully integrates TIDE, providing easy access for everyday use while supporting biotechnology companies and CROs working in regulated environments.
Whether you're optimizing CRISPR experiments in academia or preparing gene-editing workflows for clinical development, TIDE Genetics now brings everything into one place. It connects the classic TIDE application, trusted by over 100,000 users for more than a decade, with the website, enabling you to optimize any gene-editing project while staying in the loop.
The core of TIDE remains unchanged—simple, accurate, and free—and is now complemented by new features and support. Whenever questions arise, you can easily contact our team to discuss strategies to get projects unstuck. The website also provides updates on the company and relevant research that advances the field.
What You'll Find Inside TIDE Genetics
The website makes the case for why TIDE works, with a clear overview of the science behind Sanger sequencing and how it supports real research and business objectives.
With GAMP5- and GxP-compliant applications, TIDE supports the transition from large-scale sequencing experiments to regulatory-ready candidates.
Further down, you'll meet the TIDE Genetics team working to enhance users' gene-editing experience.
And finally, we want to build a community with you around the TIDE application. That's why we started an editorial page offering our visitors scientific content that simplifies and organizes the most relevant yet scattered gene-editing information available. You'll find short, practical monthly posts that discuss relevant research and advances in gene editing and genomic sequencing, along with company updates.
Did you, for example, know that CASGEVY, the first-ever FDA-approved CRISPR-associated therapy, uses TIDE to validate its potency assays? Our first article explains why a groundbreaking therapy for sickle-cell disease and β-thalassemia chooses simplicity over high-resolution sequencing.
That's the kind of story we want to keep telling, where a simple, trusted tool quietly shapes how gene editing gets done.
Where Do You Go From Here?
TIDE Genetics wants to build this community with you and ensure that academic researchers and biotech companies get the most out of gene editing and analysis with TIDE. Get in touch with one of our experts with a simple click and start the conversation. Who knows? Maybe your work will be highlighted next in our knowledge repository.